Israeli AI Startup PhaseV Secures USD 50m
Israel-based PhaseV, a startup transforming clinical trials through artificial intelligence, has raised USD 50 million in a Series A round. The investment was co-led by US venture capital firms Accel and Insight Partners, with further support from Viola Ventures, EXOR, and LionBird. This brings the company’s total funding to USD 65 million.
Founded by Raviv Pryluk and Elad Berkman, PhaseV offers a proprietary AI platform designed to optimize drug development by detecting trial design weaknesses and improving data interpretation ahead of regulatory submission. The technology aims to streamline decision-making and increase clinical trial efficiency for pharmaceutical and biotech companies.
Erdinast, Ben Nathan, Toledano represented PhaseV in the transaction, with the legal team comprising Viva Gayer, Amit Horovitz, Dr. Eran Lempert and Tal Alon (Tax).
